A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children

被引：8
作者：
Wang, Mingyue [1 ,2 ,3 ,4 ]
Gao, Xing-Hua [1 ,2 ,3 ,4 ]
Zhang, Li [1 ,5 ]
机构：
[1] China Med Univ, Hosp 1, Dept Dermatol, Shenyang 110001, Peoples R China
[2] China Med Univ, NHC Key Lab Immunodermatol, Shenyang, Peoples R China
[3] China Med Univ, Key Lab Immunodermatol, Minist Educ, Shenyang, Peoples R China
[4] Natl & Local Joint Engn Res Ctr Immunodermatol The, Shenyang, Peoples R China
[5] China Med Univ, Hosp 1, Dept Dermatol, Shenyang 110001, Peoples R China
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2024年 / 18卷
基金：
国家重点研发计划;
关键词：
atopic dermatitis; dupilumab; infant; child; treatment; ADULTS; INFLAMMATION; MANAGEMENT;
D O I：
10.2147/DDDT.S457761
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Atopic dermatitis (AD), a common pruritic and chronic inflammatory skin disease, has a major impact on a patient's quality of life. It is characterized by dry, itchy, and eczema-like rashes. AD is more prevalent in young children and has been linked to a variety of other allergy disorders. Traditional drug therapy has certain limitations for treating young children with AD. However, biologics have good clinical application prospects in the medical treatment of young patients. Dupilumab, a fully human monoclonal antibody, specifically binds to the IL-4 R alpha subunit, inhibiting IL-4 and IL-13 signaling and blocking the occurrence of type 2 inflammatory response. It has a good effect on treating infants and children with moderate-to-severe AD. This review explores the safety and efficacy of dupilumab in the treatment of AD in infants and children and the impact of early intervention on AD progression, with the aim of informing clinical practice in the use of dupilumab for the treatment of young patients with AD.
引用
收藏
页码：941 / 951
页数：11
相关论文
共 62 条
[1]   Conjunctivitis in dupilumab clinical trials [J].
Akinlade, B. ;
Guttman-Yassky, E. ;
de Bruin-Weller, M. ;
Simpson, E. L. ;
Blauvelt, A. ;
Cork, M. J. ;
Prens, E. ;
Asbell, P. ;
Akpek, E. ;
Corren, J. ;
Bachert, C. ;
Hirano, I. ;
Weyne, J. ;
Korotzer, A. ;
Chen, Z. ;
Hultsch, T. ;
Zhu, X. ;
Davis, J. D. ;
Mannent, L. ;
Hamilton, J. D. ;
Teper, A. ;
Staudinger, H. ;
Rizova, E. ;
Pirozzi, G. ;
Graham, N. M. H. ;
Shumel, B. ;
Ardeleanu, M. ;
Wollenberg, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) :459-473
[2]   IL-4 receptor α is an important modulator of IL-4 and IL-13 receptor binding:: Implications for the development of therapeutic targets [J].
Andrews, Allison-Lynn ;
Holloway, John W. ;
Holgate, Stephen T. ;
Davies, Donna E. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (12) :7456-7461
[3]   Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma [J].
Bansal, Ashish ;
Simpson, Eric L. ;
Paller, Amy S. ;
Siegfried, Elaine C. ;
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Corren, Jonathan ;
Sher, Lawrence ;
Guttman-Yassky, Emma ;
Chen, Zhen ;
Daizadeh, Nadia ;
Kamal, Mohamed A. ;
Shumel, Brad ;
Mina-Osorio, Paola ;
Mannent, Leda ;
Patel, Naimish ;
Graham, Neil M. H. ;
Khokhar, Faisal A. ;
Ardeleanu, Marius .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (01) :101-115
[4]   The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study [J].
Barbarot, Sebastien ;
Silverberg, Jonathan, I ;
Gadkari, Abhijit ;
Simpson, Eric L. ;
Weidinger, Stephan ;
Mina-Osorio, Paola ;
Rossi, Ana B. ;
Brignoli, Lysel ;
Mnif, Tarek ;
Guillemin, Isabelle ;
Fenton, Miriam C. ;
Pellan, Marine ;
Mahajan, Puneet ;
Delevry, Dimittri ;
Bansal, Ashish ;
Eckert, Laurent .
JOURNAL OF PEDIATRICS, 2022, 246 :220-+
[5]   Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis [J].
Berdyshev, Evgeny ;
Goleva, Elena ;
Bissonnette, Robert ;
Bronova, Irina ;
Bronoff, Anna Sofia ;
Richers, Brittany N. ;
Garcia, Shannon ;
Ramirez-Gama, Marco ;
Taylor, Patricia ;
Praestgaard, Amy ;
Agueusop, Inoncent ;
Jurvilliers, Pauline ;
Boguniewicz, Mark ;
Levit, Noah A. ;
Rossi, Ana B. ;
Zhang, Annie ;
Leung, Donald Y. M. .
ALLERGY, 2022, 77 (11) :3388-3397
[6]   Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials [J].
Blauvelt, A. ;
Rosmarin, D. ;
Bieber, T. ;
Simpson, E. L. ;
Bagel, J. ;
Worm, M. ;
Deleuran, M. ;
Katoh, N. ;
Kawashima, M. ;
Shumel, B. ;
Chen, Z. ;
Rossi, A. B. ;
Hultsch, T. ;
Ardeleanu, M. .
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (01) :196-197
[7]   Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE) [J].
Blauvelt, Andrew ;
Guttman-Yassky, Emma ;
Paller, Amy S. ;
Simpson, Eric L. ;
Cork, Michael J. ;
Weisman, Jamie ;
Browning, John ;
Soong, Weily ;
Sun, Xian ;
Chen, Zhen ;
Kosloski, Matthew P. ;
Kamal, Mohamed A. ;
Delevry, Dimittri ;
Chuang, Chien-Chia ;
O'Malley, John T. ;
Bansal, Ashish .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) :365-383
[8]   Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks [J].
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Simpson, Eric L. ;
Chen, Zhen ;
Zhang, Annie ;
Shumel, Brad .
DERMATOLOGY AND THERAPY, 2022, 12 (01) :223-231
[9]   Biologics in the management of childhood atopic dermatitis [J].
Butala, Sneha ;
Paller, Amy S. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (03) :681-685
[10]  
Cabanillas Beatriz, 2022, Dermatitis, DOI 10.1097/DER.0000000000000905
1234567